









Markets
/
Stocks
/
nasdaq-kala
/

KALA BIO Inc

KALA

19.630USD

+2.095+11.95%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

131.11MMarket Cap

LossP/E TTM



KALA BIO Inc

19.630

+2.095+11.95%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

71 / 506

Overall Ranking

165 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

30.750

Target Price

+75.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Undervalued

The company’s latest PE is -3.30, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 4.39M shares, increasing 5.31% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 469.23K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.82, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.82

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.74

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.77

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.04

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.95, which is -86.17% below the recent high of -0.41 and 79.79% above the recent low of -0.60.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for KALA BIO Inc is 31.50, with a high of 35.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

30.750

Target Price

+75.36%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

KALA BIO Inc

KALA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.61, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 22.78 and the support level at 10.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.61

Change

0.23

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.588

Buy

RSI(14)

78.147

Buy

STOCH(KDJ)(9,3,3)

76.018

Neutral

ATR(14)

2.064

High Vlolatility

CCI(14)

90.553

Neutral

Williams %R

10.069

Overbought

TRIX(12,20)

3.703

Sell

StochRSI(14)

36.550

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

18.441

Buy

MA10

17.157

Buy

MA20

14.331

Buy

MA50

10.014

Buy

MA100

7.106

Buy

MA200

6.849

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

1.20M

Cormorant Asset Management, LP

603.03K

SR One Capital Management, LP

598.94K

Perceptive Advisors LLC

277.61K

Woodline Partners LP

258.77K

AIGH Capital Management, LLC.

147.73K

+63.29%

The Vanguard Group, Inc.

Star Investors

152.78K

+185.19%

Adar1 Capital Management LLC

298.95K

+35.66%

UBS O'Connor LLC

170.92K

-4.48%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.07, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -1.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.